Company / Revenue
Kiniksa Pharmaceuticals International, plc Revenue History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$677.6M
FY2025
5-year range
$38.5M / $677.6M
FY2021-FY2025
Trend
+60.1%
vs FY2024
Sector context
#54 of 155
Health Care
What the data says
At $678M, Kiniksa Pharmaceuticals International, plc's revenue ranks #54 of 155 in the Health Care sector. Revenue has increased for 4 consecutive years, from $39M in FY2021 to $678M in FY2025.
Based on SEC 10-K filings.
$678M in FY2025 with a 3-year CAGR of +45.5%.
Improved from $270M to $678M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +45.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#54 of 155 in Health CareTop 35% of 155This company $677.6M Sector average $4.5B
▼
-84.8% below sector average
Key checks
Key Insights
- Kiniksa Pharmaceuticals International, plc's revenue has grown for 4 consecutive years.
- 3-year CAGR of +45.5%, indicating consistent growth.
- In FY2025, revenue increased 60.1% year-over-year.
- Ranks #54 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Negative profit margin: -10.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $677.6M | +60.1% |
| FY2024 | $423.2M | +56.6% |
| FY2023 | $270.3M | +22.7% |
| FY2022 | $220.2M | +471.2% |
| FY2021 | $38.5M | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026